Drug Profile


Alternative Names: CS 610; Galardin; GM 6001

Latest Information Update: 17 Aug 2012

Price : $50

At a glance

  • Originator University of Florida
  • Developer Arriva Pharmaceuticals; Quick-Med Technologies
  • Class Antineoplastics; Eye disorder therapies; Indoles; Small molecules
  • Mechanism of Action Matrix metalloproteinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Preclinical Chemical burns
  • Discontinued Cancer; Chronic obstructive pulmonary disease; Corneal ulcer; Diabetic retinopathy

Most Recent Events

  • 31 Dec 2009 Ilomastat is still in preclinical trials for Chemical burns in USA
  • 07 Apr 2008 Ilomastat is still in Preclinical trials for Chronic obstructive pulmonary disease in USA
  • 29 Aug 2007 Discontinued - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top